Use of aspirin, other nonsteroidal anti-inflammatory drugs and acetaminophen and risk of endometrial cancer: the Epidemiology of Endometrial Cancer Consortium
A partir de données de 7 études de cohorte et de 5 études cas-témoins incluant 7 120 patientes atteintes d'un cancer de l'endomètre et 16 069 témoins, cette étude évalue l'association entre une utilisation d'aspirine et d'autres anti-inflammatoires non stéroïdiens et le risque de développer la maladie en fonction de l'indice de masse corporelle
Background : Regular use of aspirin has been associated with a reduced risk of cancer at several sites but the data for endometrial cancer are conflicting. Evidence regarding use of other analgesics is limited. Patients and methods : We pooled individual-level data from seven cohort and five case-control studies participating in the Epidemiology of Endometrial Cancer Consortium including 7,120 women with endometrial cancer and 16,069 controls. For overall analyses, study-specific odds ratios (ORs) and 95% confidence intervals (CI) were estimated using logistic regression and combined using random-effects meta-analysis; for stratified analyses we used mixed-effects logistic regression with study as a random effect. Results : At least weekly use of aspirin and non-aspirin (NA) NSAIDs was associated with an approximately 15% reduced risk of endometrial cancer among both overweight and obese women (OR = 0.86 [95%CI 0.76-0.98] and 0.86 [0.76-0.97], respectively, for aspirin; 0.87 [0.76-1.00] and 0.84 [0.74-0.96], respectively, for NA-NSAIDs). There was no association among women of normal weight (BMI <25 kg/m2, PHeterogeneity=0.04 for aspirin, PHeterogeneity=0.003 for NSAIDs). Among overweight and obese women, the inverse association with aspirin was stronger for use 2-6 times/week (OR = 0.81, 95%CI 0.68-0.96) than for daily use (0.91, 0.80-1.03), possibly because a high proportion of daily users use low-dose formulations. There was no clear association with use of acetaminophen. Conclusion : Our pooled analysis provides further evidence that use of standard-dose aspirin or other NSAIDs may reduce risk of endometrial cancer among overweight and obese women.
Annals of Oncology 2018